ClinicalTrials.gg
Not yet recruitingNCT04465968DEEP_OCEANUpdated Jul 10, 2020

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

A Phase 3 interventional study of Cisplatin and S1 in Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB and Non Small Cell Lung Cancer Stage III, sponsored by National Cancer Center Hospital East. Not yet recruiting. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by National Cancer Center Hospital East · Phase 3, Interventional, and Treatment

How we know · 11 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
44th of 94
84 · median 74
Started
2020
with 13 others
Phase 3
17 of 94
3 open now
Primary completion
2027-08
later than 27 of 36 live
Registered
63rd of 94
by date

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 44th largest by planned enrollment, is one of 14 that started in 2020, is one of 17 in phase 3, reaches primary completion later than 27 of the 36 other live ones, and was the 63rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST

Read the detailed description

To evaluate the safety and efficacy of multimodality treatment of pre- and post-operative durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST

03

Conditions studied

  • Superior Sulcus Tumor
  • Non-small Cell Lung Cancer Stage IIB
  • Non Small Cell Lung Cancer Stage III

Keywords

  • Superior Sulcus Tumor
  • Pancoast Tumor
  • Non-Small Cell Lung Cancer
  • Durvalumab
  • Multi-modality therapy
  • Neoadjuvant therapy
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A definite diagnosis of non-small cell lung cancer has been obtained by from the primary lesion.
  2. Meet all of the following (UICC-TNM classification 8th edition). I. Regarding the primary lesion, meet one of the following on chest CT. i. Direct invasion of the chest wall at or above the height of the first rib (at least invasion of the parietal pleura) ii. Direct invasion of the subclavian artery or vein II. Regarding regional lymph nodes, meet either of the following by chest CT and FDG-PET/CT. is also considered if lymph node metastasis is determined by either chest CT or FDG-PET/CT.

    i. cN0 ii. cN1 and no metastases to #10, #11, and #12 lymph nodes iii. cN3 (ipsilateral supraclavicular lymph node metastasis) and no metastases in regional lymph nodes (N1 and N2) other than "#13, #14 lymph nodes" III. No distant metastases (including intrapulmonary metastases in the same ling lobe and in a different lung lobe on the same side) on imaging tests including FDG-PET/CT

  3. It is judged that radical resection is possible by lobectomy (including bilobectomy for 2 lobes), which satisfies the following [1] and [2].

    I. The board respiratory surgeon judges that none of the following is true based on the image findings.

    i. There is vertebral body infiltration that requires total spondylectomy ii. Presence of spinal cord infiltration iii. Invaded trachea or tracheal bifurcation iv. Invasion of aortic arch or ascending aorta v. Invading brachial plexus at C8 or higher vi. Esophageal infiltration that requires esophageal reconstruction for resection vii. Pneumonectomy is required for radical resection II. Meet all of the following. i. Predicted postoperative forced expiratory volume of 1 second (.0) ≥ 800 mL within 56 days before registration ii. SpO2 > 93% (room air) with the latest inspection value within 14 days before registration

  4. Consult with the radiotherapy doctor and it is judged that all of the following are met.

    I. Radiation therapy is possible according to the protocol II. The irradiation field does not reach the hilum

  5. The age of the registration date is 20 years or older and 75 years or yonger.
  6. Performance status (PS) is 0 or 1 according to standards (PS must be described in medical records)
  7. The presence or absence of is not required.
  8. No history of following surgery irrespective of whether for a benign or malignant lesion.

    I. Thoracoscopic surgery or thoracotomy with excision of the affected lung or esophagus or mediastinum (however, a history of thoracoscopic surgery without wedge resection or lung, esophagus, or mediastinal resection (eg, pleural biopsy)) is allowed) II. Median sternotomy surgery (with or without organ resection) III. Pulmonary resection other than wedge resection of the contralateral lung (whether open-heart surgery or thoracoscopic surgery)

  9. There is no history of chemotherapy, including treatment for other cancer types (including molecular targeted therapies and ). However, the history of drug therapy as therapy is allowed if it was completed more than 3 years ago. In addition, a history of hormone therapy for other cancer types is allowed.
  10. If there is a history of radiotherapy including other cancer types, the lung, hilum, mediastinum, and supraclavicular fossa are not included in the irradiation field.
  11. Chest CT does not show interstitial pneumonia or pulmonary fibrosis.
  12. No history of complication of disease or chronic or recurrent autoimmune disease. However, patients with type 1 diabetes which is well controlled by appropriate treatment, hyperthyroidism/hypothyroidism that requires only antithyroid drug/hormone replacement therapy, autoimmune skin disease that does not require systemic treatment (Pemphigus, psoriasis vulgaris, pemphigus vulgaris, vitiligo), and celiac disease controlled only by dietary control are regarded as eligible if they have been inactive in the past 5 years, even with a history of autoimmune complications or history.
  13. No surgical treatment with general anesthesia within 14 days (2 weeks) before registration.
  14. No systemic administration of , other drugs, or immunoglobulins within 28 days (4 weeks) before registration. However, those that meet the following conditions are allowed.

    I. Intranasal/inhalation/topical steroid injection or local steroid injection (for example, intra-articular injection) II. Systemic administration of steroid drugs at a dose of 10 mg/day or less in terms of prednisolone III. Steroids as premedication (eg CT premedication)

  15. Can be taken orally.
  16. No ischemic changes were observed on the latest 12-lead within 28 days before registration. However, if a 12-lead electrocardiogram shows ischemic changes, echocardiography, exercise electrocardiography, etc. should be performed, and if it is judged that new treatment for ischemic heart disease is not necessary, it is qualified.
  17. The latest inspection value within 14 days before registration (possible on the same day two weeks before the registration date) satisfies all of the following.

    I. White blood cell count ≧4,000/mm3 II. ≥ 11.0 g/dL (no blood transfusion within 14 days before the blood sampling date of the test used for registration) III. count ≧10×104 /mm3 IV. Total ≤ 2.0 mg/dL V. ≤ 75 U/L VI. ALT ≤ 75 U/L VII. Serum creatinine ≤ 1.2 mg/dL

  18. Written from the patient to participate in the study.
  19. The attending physician can judge that the enrolled patients understand the treatment and evaluation schedule of this study and can comply with them.

Exclusion criteria

Exclusion Criteria:

  1. Having active double cancer (simultaneous double cancer/multiple cancer and metachronous double cancer/multiple cancer with a disease-free period of 3 years or less, even if the disease-free period is less than 3 years, clinical The 5-year relative survival rate is similar to that of stage I prostate cancer, clinical stage 0 completely responded to radiation therapy, stage I laryngeal cancer, and complete excision of the following pathological stage cancers. History of cancer equivalent to 95% or more is not included in active double cancer/multiple cancer). Gastric cancer "adenocarcinoma (general type)": Stage 0-I, colon cancer (adenocarcinoma): Stage 0-I, rectal cancer (adenocarcinoma): Stage 0-I, esophageal cancer (squamous cell carcinoma, glandular) Squamous cell carcinoma, basal cell carcinoma): Stage 0, breast cancer (non-invasive ductal carcinoma, lobular carcinoma): Stage 0, breast cancer (invasive ductal carcinoma, lobular invasive carcinoma, Paget's disease): 0 Stage-IIA, endometrial cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): Stage I, prostate cancer (adenocarcinoma): Stage I-II, cervical cancer (squamous cell carcinoma): Stage 0, thyroid cancer (Papillary cancer, follicular cancer): stage I, stage II, stage III, renal cancer (clear cell carcinoma, chromophobe cell carcinoma): stage I, non-melanoma skin cancer, malignant melanoma without a definite diagnosis, etc. Lesions of intramucosal cancer
  2. Has an infectious disease that requires systemic treatment (including active pulmonary tuberculosis).
  3. When registering, a fever of 38.0°C or higher is generated.
  4. Women who are pregnant, possibly pregnant, within 28 days of delivery, or breastfeeding. A man who wants a partner to become pregnant. Or a reproductive male or female patient who is not willing to use an effective by Week 13 (Day 91) after the last dose of durvalumab (see 6.4.7.).
  5. Participation in the study is considered to be difficult due to the combination of mental illnesses or symptoms that impair daily life.
  6. Continuous systemic administration (oral or intravenous) of drugs or other drugs in excess of 10 mg/day in terms of prednisolone.
  7. With uncontrolled diabetes.
  8. With uncontrolled hypertension.
  9. A gastrointestinal disorder accompanied by uncontrolled diarrhea.
  10. With unstable angina (angina with onset or exacerbation of attack within the last 3 weeks) or a history of myocardial infarction within 6 months.
  11. Poor valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, congestive heart failure, and arrhythmia.
  12. Chest CT reveals severe emphysema.
  13. Either HBs antigen, antibody, or HIV1/2 antibody is positive.
  14. Continuous use of flucytosine (Ancotil®) is required.
  15. Participating in another clinical trial (excluding observational studies) during the 6 months prior to enrollment.
  16. A history of allogeneic organ transplant.
  17. A history of active primary immunodeficiency.
  18. (BCG, polio, measles-rubella mixture, measles, rubella, mumps, chickenpox, yellow fever, rotavirus, etc.) have been administered within 30 days before registration.
  19. Has or allergy to the test drug or its additives used in this test.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    CRT + Durvalumab ± Surgery + Durvalumab

    Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.

    Drug: Cisplatin · Drug: S1 · Radiation: concurrent radiotherapy · Drug: Durvalumab · Procedure: Surgery

Interventions

  • Cisplatin 60 mg/m2, IV, day 1

  • DrugS1

    Drug pages: TegafurStudies of TegafurTegafur pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GimeracilStudies of GimeracilGimeracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Oxonic AcidStudies of Oxonic AcidOxonic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    80 - 120 mg/day, PO, day 1-14

  • Radiationconcurrent radiotherapy

    66 Gy/33 Fr

  • preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.

  • ProcedureSurgery

    Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.

  • (For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy. Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1

06

What researchers measure

Primary outcomes

  1. 3-year overall survival rate (3y-OS)

    3-year overall survival rate

    Time frame: 3 years

Secondary outcomes

  1. 3-year progression-free survival rate (3y-PFS)

    3-year progression-free survival rate

    Time frame: 3 years

  2. 5-year progression-free survival rate (5y-PFS)

    5-year progression-free survival rate

    Time frame: 5 years

  3. 5-year overall survival rate (5y-OS)

    5-year overall survival rate

    Time frame: 5 years

  4. Mode of recurrence

    Mode of recurrence in surgical cases

    Time frame: 5 years

  5. Local recurrence rate

    Proportion of local failure in surgical cases

    Time frame: 5 years

  6. Objective response rate (ORR)

    Objective response rate according to RECIST and iRECIST

    Time frame: 1 year 6 months

  7. Resection rate

    Proportion of surgical cases

    Time frame: 1 year 6 months

  8. Pathological complete resection rate (R0 rate)

    Proportion of pathologcal complete resection in surgical cases

    Time frame: 1 year 6 months

  9. Pathological complete response rate (pCR rate)

    Proportion of pathologcal complete response in surgical cases

    Time frame: 1 year 6 months

  10. Major pathological response rate (MPR rate)

    Determination of major pathologic response rate is based on the method by Hellmann et al. on the pathological section. The percentage of residual tumor cells is calculated as viable tumor cells / tumor area × 100 (%). Tumor area includes viable tumor cells and interstitial tissue such as fibrosis, necrosis, and inflammatory cells.

    Time frame: 1 year 6 months

  11. Operation time

    Operation time in surgical cases

    Time frame: 1 year 6 months

  12. Blood loss

    Intraoperative blood loss in surgical cases

    Time frame: 1 year 6 months

  13. Adverse event rate

    Time frame: 1 year 6 months

  14. Incidences of serious adverse events

    Time frame: 1 year 6 months

  15. Incidences of adverse events

    Time frame: 1 year 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2020; primary completion for Aug 2027, 83 months later.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 83 months is close to that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2020
First posted
Jul 10, 2020
StartEst.
Sep 1, 2020
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2030
Last update
Jul 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04465968
Lead sponsor
National Cancer Center Hospital East
Collaborators
AstraZeneca, Japan Agency for Medical Research and Development, Japan Clinical Oncology Group
Responsible party
Masahiro Tsuboi (MD, National Cancer Center Hospital East) — Principal investigator
First posted
Jul 10, 2020
Start date
Sep 1, 2020 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Jul 10, 2020

Study contacts

Masahiro Tsuboi, MD
Contact
mtsuboi@east.ncc.go.jp
+81-4-7133-1111 ext. 91373
Keiju Aokage, MD
Contact
kaokage@east.ncc.go.jp
+81-4-7133-1111 ext. 91483

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion